CriticalAntianginal – late sodium current inhibitor×Antitubercular, rifamycin derivative
Updated · Methodology
Mechanism
The liver and gut break down most of a ranolazine dose through the enzyme CYP3A4 and a smaller part through CYP2D6 (ranolazine label, US Food and Drug Administration, FDA). With repeated doses, rifabutin induces liver CYP3A4 enzymes and can lower the levels of drugs that they metabolise. Kinetic data suggest that induction is complete by about day 5 and that rifabutin is a 2–3 times weaker inducer than rifampicin (rifabutin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Rifampicin 600 mg daily lowers ranolazine levels by about 95% (ranolazine SmPC, European Medicines Agency, EMA, and ranolazine FDA label). The US ranolazine label puts rifabutin on the same list of CYP3A inducers (ranolazine FDA label). The documents give no figures for rifabutin itself. In turn, ranolazine is a weak CYP3A4 inhibitor (ranolazine SmPC, EMA), and drugs that inhibit CYP3A4 can raise rifabutin levels (rifabutin SmPC, AEMPS), but the documents do not describe this for ranolazine.
Symptoms
Ranolazine is given to adults with stable angina as an add-on when first-line antianginal drugs, such as beta-blockers and calcium antagonists, do not control symptoms or are not tolerated (ranolazine summary of product characteristics, SmPC, European Medicines Agency, EMA). Rifabutin is a CYP3A4 inducer (rifabutin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS), and ranolazine is expected to lose its effect with such drugs (ranolazine SmPC, EMA). Angina attacks (pressing pain behind the breastbone on exertion) may then come back or become more frequent. The fall in ranolazine levels itself causes no symptoms.
Management
The combination is contraindicated: ranolazine must not be taken with CYP3A inducers, and the US label names rifabutin among them (ranolazine label, US Food and Drug Administration, FDA). The European ranolazine summary of product characteristics (SmPC) does not name rifabutin, but it says not to use ranolazine in patients taking CYP3A4 inducers and to avoid starting it while they are taken (ranolazine SmPC, European Medicines Agency, EMA). By its own documents, rifabutin is a CYP3A4 inducer (rifabutin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, and rifabutin FDA label). It is a weaker inducer than rifampicin, and the clinical impact of its interactions is likely to be smaller (rifabutin SmPC, AEMPS). Still, some effect on the same drugs can be expected (rifabutin FDA label), and the US ranolazine label lists rifabutin together with rifampicin (ranolazine FDA label). Tell the patient that ranolazine must not be taken with rifabutin or other such drugs (ranolazine FDA label). The rifabutin documents do not mention ranolazine, and no document gives an interval between stopping rifabutin and starting ranolazine.
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Ranolazine extended-release tablets (Zydus Lifesciences) – prescribing information (2026)– FDA label, Zydus Lifesciences, DailyMed setid d74f3dea-7357-4e9a-be9a-2f498a44108a, version 5, 09/2026, sections 2.2, 4, 5.1, 7.1 and 7.2
- AEMPS: Ficha técnica: Rifabutina (nº registro 60228), sección 4.5 (2026)– AEMPS, CIMA, nº registro 60228, revisión 04/2026, secciones 4.4 y 4.5
- FDA: Rifabutin capsules USP, Mylan (rifabutin) prescribing information (2026)– FDA, DailyMed setid c2026b67-4755-4236-96b6-a6b5e7399707, revisión 07/2026 (versión 14), Warnings (Uveitis) y Precautions, Drug Interactions, tabla 2
- EMA: Ficha técnica: Ranolazina, Ranexa (EU/1/08/462), sección 4.4 (2026)– EMA, Ranexa 375 mg comprimidos de liberación prolongada (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 08462001, consultada 10/2026, sin fecha de revisión en CIMA, secciones 4.1, 4.4 y 4.5